INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) has revealed findings from its latest Phase 3b study, indicating a reduction in amyloid-related imaging abnormalities with edema/effusion (ARIA-E) among early symptomatic Alzheimer's disease patients. The study, TRAILBLAZER-ALZ 6, assessed the effects of different dosing regimens of the drug donanemab on ARIA-E rates and amyloid clearance.
The research introduced a modified dosing approach, where one vial of donanemab was shifted from the first to the third infusion, leading to a notable decrease in ARIA-E incidence—from 24% to 14%—compared to the standard regimen used in the pivotal Phase 3 clinical trial. This modified titration maintained similar amyloid plaque and P-tau217 reduction rates as the standard regimen.
The TRAILBLAZER-ALZ 6 study encompassed four treatment arms, with one following the standard monthly dosing and the other three employing alternative dosing schedules with the same total drug quantity. The modified titration, which met predefined success criteria, showed the most significant ARIA-E reduction, particularly among patients with the apolipoprotein E (APOE4) homozygote genetic risk factor.
Despite the altered dosing, pharmacokinetic analysis confirmed equivalent cumulative exposure between the modified titration and the standard dosing regimen. The study also reported a comparable safety profile across different dosing arms, with no new safety concerns identified. There was one incident of a participant in the modified titration arm experiencing stroke-like symptoms, followed by death due to cerebral intraparenchymal hemorrhage after treatment with tissue-type plasminogen activator.
Donanemab, marketed as Kisunla™, is approved for use in the United States, Japan, Great Britain, and other countries for treating mild cognitive impairment and mild dementia stages of early symptomatic Alzheimer's disease. The drug is administered intravenously once a month, with an initial dose of 700 mg for the first three doses, followed by 1400 mg thereafter.
Lilly plans to discuss these findings with global regulators, aiming for a potential label update for Kisunla. The company continues to investigate donanemab in multiple clinical trials, including studies focused on preclinical Alzheimer's disease and a registration trial for early symptomatic Alzheimer's disease in various geographies.
The information presented is based on a press release statement from Eli Lilly and Company.
In other recent news, pharmaceutical giant Eli Lilly and Company continues to make strides in various areas. The company announced a fourth-quarter dividend of $1.30 per share, following its tradition of returning value to shareholders. In terms of product developments, Eli Lilly reported positive long-term results from its Phase 3 study of mirikizumab, a drug used in the treatment of ulcerative colitis and Crohn's disease. The company also plans to launch its weight-loss medication, Mounjaro, in Hong Kong after obtaining government approval.
Eli Lilly's EBGLYSS, a drug for moderate-to-severe atopic dermatitis, has shown promise in improving skin conditions and reducing itchiness. Meanwhile, the company has initiated legal action against Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine of Nevada for allegedly selling counterfeit versions of its weight-loss drug Zepbound.
Leerink Partners has maintained its Outperform rating on Eli Lilly shares, indicating confidence in the company's performance. These are some of the recent developments in the company's operations and products. It's important to remember that this information is based on recent reports and does not predict future outcomes or performance.
InvestingPro Insights
Eli Lilly's latest research findings on donanemab for Alzheimer's treatment align with the company's strong market position and financial performance. According to InvestingPro data, Eli Lilly boasts a substantial market capitalization of $813.13 billion, reflecting investor confidence in its innovative pharmaceutical pipeline.
The company's revenue growth is particularly noteworthy, with a 31.87% increase over the last twelve months as of Q2 2024, and an even more impressive 35.98% quarterly growth. This robust financial performance underscores Lilly's ability to bring successful drugs to market, potentially including donanemab.
InvestingPro Tips highlight Lilly's strength in the pharmaceutical industry. The company is recognized as a "Prominent player in the Pharmaceuticals industry" and has demonstrated a "High return over the last year." These factors suggest that Lilly is well-positioned to capitalize on breakthroughs like the donanemab study results.
Moreover, Lilly's commitment to shareholder value is evident in its dividend history. An InvestingPro Tip notes that the company "Has maintained dividend payments for 54 consecutive years," indicating financial stability and a long-term focus that supports ongoing research and development efforts.
For investors seeking more comprehensive insights, InvestingPro offers 18 additional tips for Eli Lilly, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.